Type1 Diabetes Mellitus Clinical Trial
Official title:
Efficacy and Safety of Highland Barley Diet on Glucose Variability in Patients With Type 1 Diabetes Mellitus
Verified date | March 2024 |
Source | Huazhong University of Science and Technology |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Approximately 80 patients will be enrolled in the study from China and randomized in a 1:1 ratio to one of the 2 treatment arms:diabetes diet+highland barley diet; or diabetes diet. Study treatment will continue for 12 weeks. The primary efficacy measure is the change in MAGE from continuous glucose monitoring system at 12 weeks. The study consists of 3 periods: a 1-week screening (period A), a 8-day run-in period (period B) and a 12-week treatment period (period C). Continuous glucose monitoring system will be used in baseline and endpoint.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 31, 2023 |
Est. primary completion date | October 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. type 1 diabetes patients with disease duration more than one year 2. HbA1c =7.0 % and < 11.0 % 3. Men and women (non-pregnant and using a medically approved birthcontrol method) aged = 18 and = 65 years 4. BMI = 18 and = 26 kg/m2 Exclusion Criteria: 1. Type 2 diabetes or other specific types of diabetes 2. Pregnancy, preparation for pregnancy, lactation and women of childbearing age incapable of effective contraception methods 3. Uncooperative subject because of various reasons 4. Abnormal liver function, glutamic-pyruvic transaminase (ALT) and glutamic-oxaloacetic transaminase (AST) > twice the upper limits of normal 5. Impairment of renal function, serum creatinine: = 133mmol/L for female,= 135mmol/L for male 6. Serious chronic gastrointestinal diseases 7. Edema 8. Serious heart diseases, such as cardiac insufficiency (level III or more according to NYHA), acute coronary syndrome and old myocardial infraction 9. Blood pressure: Systolic blood pressure (SBP) = 180mmHg and/or diastolic blood pressure (DBP) = 110mmHg 10. White blood count (WBC) < 4.0×109/L or platelet count (PLT) < 90×109/L,or definite anemia (Hb:< 120g/L for male, < 110g/L for female), or other hematological diseases 11. Endocrine system diseases, such as hyperthyroidism and hypercortisolism 12. Experimental drug allergy or frequent hypoglycemia 13. Psychiatric disorders, drug or other substance abuse 14. Diabetic ketoacidosis and hyperosmolar nonketotic coma requiring insulin therapy 15. Stressful situations such as surgery, serious trauma and so on 16. Chronic hypoxic diseases such as pulmonary emphysema and pulmonary heart disease 17. Combined use of drugs effecting glucose metabolism such as glucocorticoid Tumor, especially bladder tumor and/or family history of bladder tumor and/or long-term hematuria |
Country | Name | City | State |
---|---|---|---|
China | Tongji Hospital, Tongji Medical College, Huazhong University of Science and technology | Wuhan | Hubei |
Lead Sponsor | Collaborator |
---|---|
Huazhong University of Science and Technology |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Average blood glucose fluctuations at endpoint and baseline | Objective to investigate the effect of combination diabetes diet and highland barley diet on glucose variability in insufficient control patients with type 1 diabetes. | from baseline to 12-week endpoint | |
Secondary | Glycated hemoglobin(endpoint)-Glycated hemoglobin(baseline) | Objective to investigate the effect of combination diabetes diet and highland barley diet on glucose control in patients with type 1 diabetes. | from baseline to 12-week endpoint | |
Secondary | insulin dose(endpoint)-insulin dose(baseline) | Objective to investigate the effect of combination diabetes diet and highland barley diet on insulin dose in patients with type 1 diabetes. | from baseline to 12-week endpoint | |
Secondary | Quality of life assessment scale SF-36(endpoint)-Quality of life assessment scale SF-36(baseline) | Objective to investigate the effect of combination diabetes diet and highland barley diet on life quality in patients with type 1 diabetes. | from baseline to 12-week endpoint | |
Secondary | Body mass index(endpoint)-Body mass index(baseline) | Objective to investigate the effect of combination diabetes diet and highland barley diet on BMI in patients with type 1 diabetes. | from baseline to 12-week endpoint | |
Secondary | beta-cell function at endpoint and baseline | Objective to investigate the effect of combination diabetes diet and highland barley diet on beta-cell function in patients with type 1 diabetes. | from baseline to 12-week endpoint | |
Secondary | Waist circumference(endpoint)-Waist circumference(baseline) | Objective to investigate the effect of combination diabetes diet and highland barley diet on waist circumference in patients with type 1 diabetes. | from baseline to 12-week endpoint |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03623113 -
The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study in Type 1 Diabetes
|
N/A | |
Withdrawn |
NCT03396484 -
Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT03117998 -
Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus
|
Phase 2 | |
Recruiting |
NCT03369821 -
EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)
|
||
Completed |
NCT03202732 -
DiabetesFlex - Patient Involvement and Patient-reported Outcome Measures in Type 1 Diabetes
|
N/A | |
Completed |
NCT03704818 -
Dapagliflozin Effects on Hypoglycemia
|
Phase 1 | |
Recruiting |
NCT03864991 -
Lifestyle Changes and Glycemic Control in T1D
|
N/A | |
Completed |
NCT03725657 -
Correlation Between Exercise and Insulin Dose in a Camp for Pediatric Type 1 Patients
|
||
Completed |
NCT02985866 -
The International Diabetes Closed Loop (iDCL) Trial: Protocol 1
|
N/A | |
Completed |
NCT03003806 -
Evaluation of the Dreamed Advisor Pro for Automated Insulin Pump Setting Adjustments in Children and Adolescents With Type 1 Diabetes- The Advice4U Pro Study
|
N/A | |
Withdrawn |
NCT04147637 -
FreeStyle Libre Plus Bluetooth Transmitter Adjunct: Can This Improve Glucose Accuracy and Reduce Burden of Hypoglycaemia
|
N/A | |
Completed |
NCT03970889 -
Real-time Reminders To Decrease Late or Missed Meal Boluses
|
N/A | |
Recruiting |
NCT04589325 -
Ixekizumab Diabetes Intervention Trial (I-DIT)
|
Phase 2 | |
Completed |
NCT03367390 -
A Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM)
|
Phase 1 | |
Completed |
NCT03738852 -
Mechanisms for Restoration of Hypoglycemia Awareness
|
Early Phase 1 | |
Completed |
NCT03406585 -
Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes
|
Phase 1/Phase 2 | |
Completed |
NCT03859856 -
Ovarian Reserve in Diabetes Mellitus
|
||
Withdrawn |
NCT04102202 -
BOL-DP-o-05 as an Add-On Treatment of Subjects With Newly Diagnosed Type 1 Diabetes Mellitus
|
Phase 1/Phase 2 | |
Terminated |
NCT03353792 -
Using an Artificial Pancreas System in Older Adult Type 1 Diabetes Mellitus Patients
|
N/A | |
Recruiting |
NCT03811470 -
China Diabetes Registry by Metabolic Management Center
|